Alemtuzumab-induced thyroid events in multiple sclerosis. A systematic review and meta-analysis
01 Pubblicazione su rivista
Scappaticcio L, Castellana M, Virili C, Bellastella G, Centanni M, Cannavò S, Campennì A, Ruggeri R M, Giovanella L, Trimboli P
ISSN: 1720-8386
Autoimmune thyroid events (ATEs) are common side effects after alemtuzumab (ALZ) therapy in patients with multiple sclerosis (MS). Our purpose was to reach more robust evidence on prevalence and outcome of the spectrum of alemtuzumab-induced autoimmune thyroid events in patients with multiple sclerosis.